X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs STRIDES PHARMA SCIENCE - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH STRIDES PHARMA SCIENCE STERLING BIOTECH/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -0.4 69.1 - View Chart
P/BV x 0.0 1.2 1.2% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 STERLING BIOTECH   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
STRIDES PHARMA SCIENCE
Mar-18
STERLING BIOTECH/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs111,147 0.9%   
Low Rs3642 0.5%   
Sales per share (Unadj.) Rs26.8317.2 8.4%  
Earnings per share (Unadj.) Rs-15.07.8 -190.7%  
Cash flow per share (Unadj.) Rs-5.525.1 -21.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs54.9274.3 20.0%  
Shares outstanding (eoy) m267.8789.50 299.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.8 9.2%   
Avg P/E ratio x-0.5114.0 -0.4%  
P/CF ratio (eoy) x-1.335.7 -3.6%  
Price / Book Value ratio x0.13.3 3.9%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m1,86280,058 2.3%   
No. of employees `0001.42.5 54.0%   
Total wages/salary Rs m5474,341 12.6%   
Avg. sales/employee Rs Th5,303.311,325.8 46.8%   
Avg. wages/employee Rs Th403.81,731.4 23.3%   
Avg. net profit/employee Rs Th-2,959.0280.1 -1,056.6%   
INCOME DATA
Net Sales Rs m7,18128,394 25.3%  
Other income Rs m43941 4.5%   
Total revenues Rs m7,22329,334 24.6%   
Gross profit Rs m9473,965 23.9%  
Depreciation Rs m2,5431,540 165.1%   
Interest Rs m4,3771,962 223.0%   
Profit before tax Rs m-5,9311,403 -422.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m-1,92497 -1,977.7%   
Profit after tax Rs m-4,007702 -570.6%  
Gross profit margin %13.214.0 94.4%  
Effective tax rate %32.46.9 467.9%   
Net profit margin %-55.82.5 -2,256.4%  
BALANCE SHEET DATA
Current assets Rs m14,33524,836 57.7%   
Current liabilities Rs m49,80918,993 262.3%   
Net working cap to sales %-494.020.6 -2,400.7%  
Current ratio x0.31.3 22.0%  
Inventory Days Days40371 568.4%  
Debtors Days Days171113 150.5%  
Net fixed assets Rs m55,43234,289 161.7%   
Share capital Rs m268895 29.9%   
"Free" reserves Rs m13,93523,651 58.9%   
Net worth Rs m14,70124,546 59.9%   
Long term debt Rs m9,47815,513 61.1%   
Total assets Rs m73,98865,437 113.1%  
Interest coverage x-0.41.7 -20.7%   
Debt to equity ratio x0.60.6 102.0%  
Sales to assets ratio x0.10.4 22.4%   
Return on assets %0.54.1 12.3%  
Return on equity %-27.32.9 -952.8%  
Return on capital %-6.46.9 -93.2%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86015,697 11.8%   
Fx outflow Rs m25735 3.4%   
Net fx Rs m1,83514,962 12.3%   
CASH FLOW
From Operations Rs m1,7191,871 91.9%  
From Investments Rs m-3,1485,826 -54.0%  
From Financial Activity Rs m1,426-10,157 -14.0%  
Net Cashflow Rs m-3-2,615 0.1%  

Share Holding

Indian Promoters % 33.9 27.7 122.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 37.8 -  
FIIs % 9.9 8.6 115.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 25.9 151.7%  
Shareholders   21,482 56,241 38.2%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty Stocks Lead(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.6% while the Hang Seng is down 0.2%.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

STRIDES SHASUN LTD Announces Quarterly Results (4QFY18); Net Profit Down 99.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, STRIDES SHASUN LTD has posted a net profit of Rs 8 m (down 99.2% YoY). Sales on the other hand came in at Rs 7 bn (down 25.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - FRESENIUS KABI ONCO. COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS